Clinical Data Nektar surges again as alopecia drug shows new promise in extension study pharminent April 20, 2026
M&A / Deals Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout pharminent April 20, 2026
Policy / Pricing FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development pharminent April 20, 2026
Other AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle pharminent April 20, 2026
M&A / Deals Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal pharminent April 20, 2026
Clinical Data Novo’s late-stage sickle cell win piles pressure on competitors pharminent April 20, 2026
Other S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer pharminent April 20, 2026
Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market pharminent April 20, 2026
Commercial The Omnichannel Gap: Building the CRM of the Future for Patient Services pharminent April 20, 2026
Policy / Pricing Trump backs psychedelics for mental health in new executive order pharminent April 20, 2026
Regulatory MSD secures EC approval for Enflonsia to prevent infant RSV infection pharminent April 20, 2026
Manufacturing Magazine: Digital twins become the new battleground for CDMOs pharminent April 20, 2026
Commercial Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool pharminent April 17, 2026
Commercial Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch pharminent April 17, 2026
Other S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting pharminent April 17, 2026
Policy / Pricing RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media pharminent April 17, 2026
Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint pharminent April 17, 2026
Regulatory Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
M&A / Deals Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions pharminent April 17, 2026
